XSTOORTI B
Market cap5mUSD
Dec 23, Last price
1.43SEK
1D
2.14%
1Q
-14.88%
Jan 2017
-39.02%
Name
Ortivus AB
Chart & Performance
Profile
Ortivus AB (publ) develops and commercializes medical technology solutions for healthcare industry in Sweden and internationally. The company offers MobiMed Monitor that monitors and measures the patient's vital parameters, such as ECG, blood pressure, and SpO2; MobiMed ePR, an electronic patient record system for documentation of treatment and events; MobiMed Life, which is designed for advanced monitoring and resuscitation; and MobiMed Cloud that supports multiplatform data sharing on Windows, Webb, IOS, and Android. It also provides support, implementation, training, and consulting services. The company was incorporated in 1985 and is headquartered in Danderyd, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 84,081 -19.55% | 104,509 10.86% | 94,272 -12.37% | |||||||
Cost of revenue | 100,479 | 97,849 | 81,705 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (16,398) | 6,660 | 12,567 | |||||||
NOPBT Margin | 6.37% | 13.33% | ||||||||
Operating Taxes | 55 | (79) | 160 | |||||||
Tax Rate | 1.27% | |||||||||
NOPAT | (16,453) | 6,739 | 12,407 | |||||||
Net income | (18,245) -409.66% | 5,892 -36.03% | 9,211 -18.72% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
Debt | ||||||||||
Debt current | 1,907 | 2,056 | 1,269 | |||||||
Long-term debt | 9,055 | 10,384 | 5,351 | |||||||
Deferred revenue | 8,545 | 6,909 | 10,049 | |||||||
Other long-term liabilities | 1,055 | 6,909 | 10,049 | |||||||
Net debt | 5,673 | 4,843 | (15,492) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (303) | (6,878) | 7,774 | |||||||
CAPEX | (423) | (6,093) | (6,702) | |||||||
Cash from investing activities | (14,762) | (6,149) | (6,702) | |||||||
Cash from financing activities | 8,726 | (1,490) | (1,240) | |||||||
FCF | 4,820 | (10,125) | 6,355 | |||||||
Balance | ||||||||||
Cash | 1,289 | 7,597 | 22,112 | |||||||
Long term investments | 4,000 | |||||||||
Excess cash | 1,085 | 2,372 | 17,398 | |||||||
Stockholders' equity | (15,482) | 2,648 | (3,343) | |||||||
Invested Capital | 47,868 | 53,101 | 56,195 | |||||||
ROIC | 12.33% | 27.57% | ||||||||
ROCE | 13.71% | 29.36% | ||||||||
EV | ||||||||||
Common stock shares outstanding | 44,307 | 44,307 | 44,307 | |||||||
Price | 4.74 -14.13% | 5.52 6.15% | 5.20 0.97% | |||||||
Market cap | 210,017 -14.13% | 244,577 6.15% | 230,399 0.97% | |||||||
EV | 215,690 | 249,420 | 214,907 | |||||||
EBITDA | (13,282) | 9,168 | 15,905 | |||||||
EV/EBITDA | 27.21 | 13.51 | ||||||||
Interest | 578 | 11 | 160 | |||||||
Interest/NOPBT | 0.17% | 1.27% |